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of steatosis on liver stiffness measurement (LSM) is still debated.
We assessed the impact of steatosis and its ultrasonographical
sign – bright liver echo pattern (BLEP) – on LSM values and on
transient elastography (TE) accuracy for the diagnosis of liver
ﬁbrosis, in a cohort of consecutive patients with Genotype 1
(G1) CHC.
Methods: Patients (n = 618) were assessed by clinical, ultrasono-
graphic and histological (Scheuer score) features. TE was per-
formed using the M probe.
Results:Male gender (p = 0.04), steatosis as continuous variable
(p <0.001), severity of necroinﬂammation (p = 0.02) and stage of
ﬁbrosis (p <0.001) were associated with LSM by multivariate lin-
ear regression analysis. Among patients within the same ﬁbrosis
stages (F0–F2 and F3–F4; F0–F3 and F4), mean LSM values,
expressed in kPa, were signiﬁcantly higher in subjects with mod-
erate-severe steatosis (P20% at liver biopsy) compared with
those without, as well as in patients with BLEP on US compared
with their counterpart. In subjects without severe ﬁbrosis (F0–
F2) and without cirrhosis (F0–F3), a higher rate of false-positive
LSM results was observed in patients with steatosis P20% com-
pared with those without (F0–F2: 35.3% vs. 17.9%; F0–F3: 38.9%
vs. 16.6%), and in patients with BLEP on US (F0–F2: 28.0% vs.
18.3%; F0–F3: 29.7% vs. 17.8%) compared with their counterpart.
Conclusions: In patients with G1 CHC, the presence of moderate-
severe steatosis, detected by histology or by US, should always be
taken into account in order to avoid overestimations of liver
ﬁbrosis assessed by TE.
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The prognosis of patients with chronic liver diseases is critically
decided by the amount of liver ﬁbrosis that accumulates over
the years as a consequence of several mechanisms of liver injury,
with the ultimate occurrence of cirrhosis and its complications
[1,2]. Liver biopsy is regarded as the gold standard procedure to
assess presence and severity of all liver diseases, including
chronic hepatitis C (CHC). However, it is an invasive procedure
carrying a certain risk of complications, and its accuracy is
affected by concerns related to inter- and/or intra-observer dis-
crepancies [3], and by other factors such as length and width of
biopsy sample, sampling errors, and inconsistency in deﬁning
histological features due to the variety of the several available
scoring systems [4,5]. Furthermore, new therapeutic strategies
against HCV infection at high efﬁcacy and with an excellent pro-
ﬁle of tolerability will be available in the near future; conse-
quently, the need for histological staging will decrease, and
non-invasive techniques for evaluation and monitoring of
patients with CHC, particularly transient elastography (TE) [6]
and ultrasonography (US) [7], will play an increasingly relevant
role.
The use of TE to estimate liver ﬁbrosis has been repeatedly
validated in different settings [8], including CHC [9–11]. Indepen-
dently of the underlying etiology, TE showed overall a good accu-
racy in diagnosing severe ﬁbrosis and cirrhosis [8,12,13], even if
its performance seems to be affected by several factors, such as
alanine aminotransferase ﬂares and severe liver necroinﬂamma-
tion [14–16], recent food intake [17], hepatic congestion [18],
extrahepatic cholestasis [19], high body mass index (BMI)
[20,21] and insulin resistance [22]. Conversely, there are contro-
versial data about the inﬂuence of liver steatosis on LSM values
and TE performance, especially in patients with CHC. Indeed,
even if a lower interobserver agreement for LSM was observed
in patients with liver steatosis compared with their counterpart
[23], several studies showed no impact of steatosis on liver stiff-
ness [10,24], others demonstrated increased LSM values in pres-
ence of high degrees of steatosis [25–27], whereas steatosis >33%
was associated with lower LSM values in NAFLD patients with
severe ﬁbrosis [28].
The aim of the present study was to assess the impact of liver
steatosis, detected by histology and US, on LSM values and on14 vol. 61 j 523–529
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accuracy of TE for ﬁbrosis diagnosis in a cohort of consecutive
biopsy-proven patients with genotype 1 (G1) CHC.Patients and methods
Patients
The study assessed consecutive patients with biopsy-proven G1 CHC, all
recruited at the Gastrointestinal & Liver Unit at the University Hospital in
Palermo, and fulﬁlling all inclusion and exclusion criteria detailed below.
Patients were included if they had a histological diagnosis of CHC (any degree
of ﬁbrosis, including cirrhosis) on a liver biopsy. G1 CHC patients were deﬁned
by the presence of serum anti-HCV and HCV-RNA, with persistently abnormal
alanine aminotransferase (ALT), and by alcohol consumption of <20 g/day in
the last year or more, evaluated by a speciﬁc questionnaire. Exclusion criteria
were: (I) advanced cirrhosis (Child-Pugh B and C); (II) hepatocellular carci-
noma; (III) other causes of liver disease, mixed etiologies and acute liver inju-
ries of any etiology on chronic liver damage, (IV) human immunodeﬁciency
virus infection; (V) previous and/or current use of steatosis-inducing drugs
or potentially hepatotoxic drugs, evaluated by interview; (VI) active intrave-
nous drug addiction.
The study was performed in accordance with the principles of the Helsinki
Declaration and its appendices, and with local and national laws, and written
informed consent was obtained from all patients.Clinical and laboratory assessment
Demographic, clinical and anthropometric data were collected at the time of liver
biopsy. The diagnosis of arterial hypertension was based on a systolic blood pres-
sure P135 mmHg and/or diastolic blood pressure P85 mmHg (measured three
times within 30 min using a brachial sphygmomanometer), or on use of blood-
pressure-lowering agents. The diagnosis of type 2 diabetes was based on the
revised criteria of the American Diabetes Association, using a value of fasting
blood glucoseP126 mg/dl on at least two occasions [29]. A current therapy with
insulin or oral hypoglycemic agents was documented in patients with a previous
diagnosis of type 2 diabetes.
A 12-h overnight fasting blood sample was drawn at the time of biopsy to
determine serum levels of ALT, platelet count, total cholesterol, HDL- and LDL-
cholesterol, triglycerides, blood glucose and insulin. IR was assessed with the
homeostasis model assessment (HOMA) method through the following equation
[30]: Insulin Resistance (HOMA-IR) = Fasting insulin (lU/ml)  Fasting glucose
(mmol/L)/22.5.
All patients were tested at the time of biopsy for HCV-RNA (RT-PCR home-
made; limit of detection: 12 IU/ml). Genotyping was performed by INNO-LiPA,
HCV II, Bayer.Liver stiffness measurement
Transient elastography was performed with the Fibroscan (Echosens, Paris,
France) medical device, using the M probe (also named as standard probe).
LSM was assessed on the same day of liver biopsy, before the procedure
and after an overnight fast, by trained operators who had previously per-
formed at least 300 determinations in patients with chronic liver disease.
As suggested by the manufacturing company and as reported in the literature
[9], we considered 10 successful acquisitions with a success rate of at least
60%, and with an interquartile range lower than 30%, as representative
measurements.Ultrasound assessment
Ultrasound assessment was performed in the morning, on the same day of liver
biopsy, by one operator (G.C.) trained for ultrasound techniques and particularly
dedicated to liver examination, using a real-time Hitachi H21 apparatus with a 2–
5 MHz, convex, multi-frequency probe. Presence of hepatic steatosis was deﬁned
through detection of Bright Liver Echo Pattern (BLEP), i.e., ﬁne, packed and high
amplitude echoes, with consequent brightness of liver, increase in liver-kidney
contrast and possible evidence of vascular blurring and deep attenuation signs
[31].524 Journal of Hepatology 201Histology assessment
All slides were evaluated by an expert pathologist (D.C.), blinded to identity, US
features and LSM values of the patients. Biopsies were classiﬁed according to
Scheuer numerical scoring system [32]. Steatosis was deﬁned as the percentage
of hepatocytes containing fat droplets, and assessed as continuous variable. It
was also classiﬁed as present at P5%, signiﬁcative at P10%, moderate-severe
at P20%, and severe at P30%.
Statistics
Continuous variables were summarized as mean ± standard deviation and cate-
gorical variables as frequency and percentage. The t test and v2 test were used
as appropriate. Multiple logistic regression models were used to assess the vari-
ables independently associated with different stages of ﬁbrosis. In these models,
the dependent variables were signiﬁcant ﬁbrosis, coded as 0 = F0 to F1 and 1 = F2
to F4; severe ﬁbrosis, coded as 0 = F0 to F2 and 1 = F3 to F4; and cirrhosis, coded
as 0 = F0 to F3 and 1 = F4. As candidate risk factors, we selected age, gender, BMI,
baseline ALT, platelet count levels, total, LDL-and HDL-cholesterol, triglycerides,
blood glucose, insulin, HOMA score, arterial hypertension, diabetes, HCV-RNA
(expressed as Log10), severe grading and moderate-severe steatosis. In addition,
a multiple linear regression analysis was performed to identify independent pre-
dictors of LSM as continuous dependent variable. As candidate risk factors, we
selected the same variables included in the above models and added stage of
ﬁbrosis as an additional independent variable. To avoid the effect of collinearity,
HOMA score, blood glucose levels and insulin levels were not included in the
same multivariate model. Receiver operating characteristic (ROC) curves were
applied to ﬁnd the best cut-off values and to identify the area under ROC curve
(AUROC) of LSM able to discriminate the different stages of ﬁbrosis. Furthermore,
descriptions of the operating characteristics (sensitivity, speciﬁcity, positive pre-
dictive value [PPV], negative predictive value [NPV], positive likelihood ratio [LR+]
and negative likelihood ratio [LR]) of US for the detection of steatosis P5%,
P10%,P20%, andP30% were calculated, with the assumption that gold standard
for the diagnosis of steatosis was histologic examination. Finally, multiple logistic
regression models for LSM values were performed, using the best LSM cut-offs for
discriminating severe ﬁbrosis and cirrhosis as dependent variables. All analysis
were performed using SPSS v. 20.0 statistical package for MacIntosh (SPSS Inc.,
Chicago, USA).Results
Patients
From January 2008 to October 2013, we included 702 consecutive
patients with G1 CHC who underwent TE, US, and liver biopsy.
Eighty-four (12%) failed to obtain 10 valid LSM acquisitions due
to obesity or to unreliable results according to manufacturer’s
recommendations (see above). Hence, 618 patients with valid
LSM acquisitions could be included in the analysis. Table 1 sum-
marizes the baseline features of these 618 patients. Mean age was
53.0 ± 12.1 years, with a male to female ratio approximately
equal. More than half of patients was in the overweight or obese
range, a quarter was hypertensive and diabetes was present in
about thirteen percent of subjects. Mean values for total, HDL-
and LDL-cholesterol, and triglycerides were within the normal
range, whereas mean HOMA values were elevated (3.2 ± 2.5).
At liver biopsy, approximately one patient in four had ﬁbrosis
P3 by Scheuer score, whereas prevalence of severe necroinﬂam-
mation (grading 3) was of 33.8%. About half of the cases had his-
tological evidence of steatosis, which was of moderate-severe
grade (P20%) in 155 cases (25.1%).
Factors associated with ﬁbrosis
Univariate and multivariate regression analyses were performed
to identify potential associations between each feature of patients4 vol. 61 j 523–529
Table 1. Baseline features of 618 patients with genotype 1 chronic hepatitis C.
Variable Genotype 1 
chronic hepatitis C
(n = 618)
Age – yr 53.0 ± 12.1
Male sex 330 (53.4%)
Body Mass Index – kg/m2 25.8 ± 3.7
Body Mass Index – kg/m2
<25
25-29.9
≥30
266 (43.1%)
269 (43.5%)
83 (13.4%)
Arterial hypertension 163 (25.4%)
Type 2 diabetes 79 (12.8%)
Alanine aminotransferase – IU/L 90.9 ± 82.7
Platelet count – x103/mm3 203.9 ± 117.1
Cholesterol – mg/dl 174.8 ± 35.8
HDL cholesterol – mg/dl 55.0 ± 17.6
LDL cholesterol – mg/dl 100.5 ± 33.1
Triglycerides – mg/dl 96.2 ± 48.0
Blood glucose – mg/dl 96.9 ± 31.8
Insulin – μU/ml 13.1 ± 8.3
HOMA 3.2 ± 2.5
Log10 HCV-RNA – IU/ml 6.3 ± 1.1
Bright liver echo pattern on ultrasound 206 (33.3%)
Liver stiffness - kPa 9.3 ± 5.3
Histology at biopsy       
Steatosis
Absent (<5%)
Present (≥5%)
Significative (≥10%)
Moderate-severe (≥20%)
Severe (≥30%)
321 (51.9%)
297 (48.1%)
263 (42.6%)
155 (25.1%)
95 (15.4%)
Grading
Stage of fibrosis
1
2
3 
115 (18.6%) 
294 (47.6%)
209 (33.8%)
0
1
2
3
4
39 (6.3%)
167 (27.0%)
237 (38.3%)
110 (17.8%)
65 (10.5%)
yr, years; IU, international units; kPa, KiloPascal; HOMA, homeostasis model
assessment; HDL, high density lipoprotein; LDL, low density lipoprotein.
Data are given as mean ± standard deviation or as number of cases (%).
JOURNAL OF HEPATOLOGYand liver ﬁbrosis at three cut-off levels: (a) signiﬁcant ﬁbrosis (F2–
F4); (b) severe ﬁbrosis (F3–F4) and (c) cirrhosis (F4) (Supplemen-
tary Table 1). Liver stiffness remained signiﬁcantly associated with
signiﬁcant (OR 1.188, 95% CI 1.111–1.269; p <0.001) and severe (OR
1.330, 95% CI 1.248–1.416; p <0.001) ﬁbrosis, and with cirrhosis (OR
1.235, 95% CI 1.170–1.304; p <0.001). The overall AUCs of these
models were 0.780 (95% CI 0.742–0.818) for signiﬁcant ﬁbrosis,
0.891 (95% CI 0.864–0.919) for severe ﬁbrosis, and 0.898 (95% CI
0.863–0.932) for cirrhosis.
Performance of US on steatosis assessment
BLEP was observed on US examination in 206 patients (33.3%).
Sensitivity, speciﬁcity, PPV, NPV, LR+ and LR of US for theJournal of Hepatology 201detection of steatosis P5%, P10%, P20%, and P30% are shown
in Table 2. Notably, sensitivity, speciﬁcity and NPVs of US for the
detection of both steatosis P20% and P30% were quite similar
(67.7%, 78.2%, and 86.4% vs. 71.6%, 73.6%, and 93.4%, respectively).
Factors associated with LSM, and accuracy of TE for ﬁbrosis
assessment
Mean LSM was 9.3 ± 5.3 kPa (range 2.7–34.0). Liver stiffness
values signiﬁcantly increased according to ﬁbrosis stage (6.9 ± 2.7
in F1; 8.0 ± 3.9 in F2; 12.5 ± 5.2 in F3; 17.0 ± 7.9 in F4; p <0.001).
Older age, male gender, high BMI, high baseline ALT, low
platelets, low cholesterol, high triglycerides, high blood glucose,
high insulin, high HOMA, steatosis as continuous variable, sever-
ity of necroinﬂammatory activity, and stage of ﬁbrosis were
linked to LSM as continuous variable at univariate analysis
(p <0.10), even if only male gender (p = 0.04), steatosis as contin-
uous variable (p <0.001), severity of necroinﬂammation
(p = 0.02), and stage of ﬁbrosis (p <0.001) remained associated
by multivariate linear regression analysis.
ROC curves identiﬁed the best cut-offs of LSM able to maxi-
mize the accuracy of TE at 7.25 kPa for the diagnosis of signiﬁcant
ﬁbrosis (AUC 0.727, sensitivity 66.3%, speciﬁcity 66.5%), at
8.95 kPa for severe ﬁbrosis (AUC 0.864; sensitivity 79.0%, speci-
ﬁcity 78.7%) and at 10.65 kPa (AUC 0.882; sensitivity 76.9%, spec-
iﬁcity 78.1%) for cirrhosis. Considering the performance of LSM in
discriminating signiﬁcant ﬁbrosis as not acceptable, we focused
on severe ﬁbrosis and cirrhosis only.
At the LSM cut-off of 8.95 kPa for severe ﬁbrosis, the false-
positive rate was 21.2% (94/443) and the false-negative rate
was 20.6% (36/175). Concerning the performance of LSM
>10.65 kPa for cirrhosis, the false-positive rate was 21.9% (121/
553) and the false-negative rate was 23.1% (15/65). Fig. 1 summa-
rizes the accuracy of LSM in diagnosing severe ﬁbrosis (Fig. 1A)
and cirrhosis (Fig. 1B) in the entire G1 CHC cohort. Of note, mod-
erate-severe steatosis and severe grading, other than ﬁbrosis
stage, were signiﬁcantly associated with LSM cut-offs of
>8.95 kPa for severe ﬁbrosis (OR 1.710; 95% CI 1.026–2.655;
p = 0.04; and OR 2.696; 95% CI 1.726–4.211; p <0.001, respec-
tively – overall AUC of the model: 0.819) and of >10.65 kPa for
cirrhosis (OR 2.119; 95% CI 1.312–3.423; p = 0.002; and OR
2.744; 95% CI 1.769–4.255; p <0.001, respectively – overall AUC
of the model: 0.827) by multivariate regression analyses.
Impact of liver steatosis and BLEP detection on LSM values and on
accuracy of TE
Due to the independent association of liver stiffness with steato-
sis, we assessed the variations of LSM values and of TE accuracy
according to presence or absence of moderate-severe steatosis
(P20%) on histological examination, and according to BLEP
detection on US, a reliable surrogate of steatosis.
Fig. 2 shows, in subgroups of patients with and without mod-
erate-severe steatosis, mean LSM values among patients with F0–
F2 ﬁbrosis stages (9.2 ± 5.1 vs. 7.0 ± 2.8; p <0.001 – Fig. 2A) and
F3–F4 ﬁbrosis stages (15.4 ± 6.9 vs. 13.2 ± 5.6; p = 0.02 –
Fig. 2B), and among patients with F0–F3 ﬁbrosis stages
(10.8 ± 5.7 vs. 7.7 ± 3.5; p <0.001 – Fig. 2C) and cirrhosis
(18.8 ± 7.5 vs. 15.9 ± 6.1; p = 0.09 – Fig. 2D). As expected, similar
results were obtained when the entire cohort was split according
to presence or absence of BLEP on US (Fig. 3). Furthermore,4 vol. 61 j 523–529 525
Table 2. Sensitivity, Speciﬁcity, Predictive Values and Likelihood Ratios of ultrasound for steatosis detection in genotype 1 chronic hepatitis C patients.
GI CHC (n = 618) Sensitivity Specificity PPV NPV LR + LR -
Steatosis ≥5% 172/297 (57.9%) 287/321 (89.4%) 172/206 (83.5%) 287/412 (69.7%) 5.46 0.47
Steatosis ≥10% 156/263 (59.3%) 305/355 (85.9%) 156/206 (75.7%) 305/412 (74.0%) 4.21 0.47
Steatosis ≥20% 105/155 (67.7%) 362/463 (78.2%) 105/206 (51.0%) 356/412 (86.4%) 3.11 0.41
Steatosis ≥30% 68/95 (71.6%) 385/523 (73.6%) 68/206 (33.0%) 385/412 (93.4%) 2.71 0.39
PPV, Positive Predictive Value; NPV, Negative Predictive Value; LR+, Positive likelihood ratio; LR, Negative likelihood ratio.
A BBiopsy-proven G1 CHC + reliable TE
n = 618
LSM <8.95 kPa
n = 385
<F3 (correct), n = 349
≥F3 (false negative), n = 36
LSM >8.95 kPa
n = 233
<F3 (false positive), n = 94
≥F3 (correct), n = 139
<F4 (correct), n = 432
F4 (false negative), n = 15
LSM <10.65 kPa
n = 447
<F4 (false positive), n = 121
F4 (correct), n = 50
LSM >10.65 kPa
n = 171
Biopsy-proven G1 CHC + reliable TE
n = 618
Fig. 1. Accuracy of transient elastography. For the prediction of severe ﬁbrosis (A) and cirrhosis (B) in patients with genotype 1 chronic hepatitis C and reliable transient
elastography.
Research Articleamong subjects without severe ﬁbrosis (F0–F2), the rate of false
positive LSM results was higher in patients with steatosis P20%
(30/85; 35.3%) compared with their counterpart (64/357;
17.9%) (Fig. 4A), and in patients with detection of BLEP (37/132;
28.0%) compared with those without (57/311; 18.3%) (Fig. 4B).
Similar differences in false positive rates were observed among
patients without cirrhosis (F0–F3) (Fig. 4C and D). Conversely,
the impact of moderate-severe steatosis and of BLEP detection
on false negative LSM results was negligible (data not shown).
In addition, ROC curves were applied to ﬁnd the best cut-off val-
ues of LSM able to discriminate severe ﬁbrosis and cirrhosis
among subgroups of patients with and without detection of BLEP.
In patients with detection of BLEP, using a LSM cut-off of 9.95 kPa
for severe ﬁbrosis (AUC 0.840, sensitivity 78.4%, speciﬁcity 78.0%)
and of 15.35 kPa for cirrhosis (AUC 0.880, sensitivity 76.2%, spec-
iﬁcity 87.0%), the false-positive rates decreased from 28.0% to
22.0%, and from 29.7% to 13.0%, respectively. In patients without
BLEP, the false-positive rates increased from 18.3% to 21.5%, and
from 17.9% to 22.8% using a LSM cut-off of 8.75 kPa for severe
ﬁbrosis (AUC 0.873, sensitivity 83.3%, speciﬁcity 78.4%) and of
10.05 kPa for cirrhosis (AUC 0.892, sensitivity 81.8%, speciﬁcity
78.0%), respectively.
Finally, although male subjects showed slightly higher mean
LSM values compared with females, a similar overall inﬂuence
of steatosis and of BLEP detection on LSM values was observed
when the entire cohort was stratiﬁed according to the gender
(data not shown).Discussion
In our cohort of 618 consecutive biopsy-proven patients with
G1 CHC, we found that steatosis, diagnosed by histology or by
US - detection of BLEP – is independently associated with526 Journal of Hepatology 201increased LSM values. As a consequence, we reported higher rates
of false positive LSM results for the non-invasive assessment of
both severe ﬁbrosis and cirrhosis by TE in patients with BLEP
on US examination compared with their counterpart.
Transient elastography is a reliable tool to identify liver ﬁbro-
sis and cirrhosis, especially in patients with CHC, where it has
been repeatedly validated [9–13]. In our cohort of G1 CHC
patients, the accuracy of TE for the assessment of liver ﬁbrosis
was good in diagnosing severe ﬁbrosis and cirrhosis, while it
was quite low for signiﬁcant ﬁbrosis, as expressed by their AUR-
OCs. These ﬁndings are in line with previously reported data from
the literature [13]. Furthermore, we identiﬁed LSM values of
7.25 kPa, 8.95 kPa, and 10.65 kPa as the best cut-offs for discrim-
inating signiﬁcant ﬁbrosis (F2–F4), severe ﬁbrosis (F3–F4), and
cirrhosis (F4), respectively. Once again, these LSM cut-off values
were comparable with those identiﬁed in other cohorts [13].
Some variability may be ascribed to the different prevalence of
signiﬁcant ﬁbrosis and of several factors inﬂuencing liver stiff-
ness independently from the amount of liver ﬁbrosis in the vari-
ous examined cohorts.
An interesting ﬁnding emerging from our data is that the pres-
ence of liver steatosis not only is clearly independently associated
with higher LSM, but it is even able to affect the overall diagnos-
tic performance of TE in patients with G1 CHC, causing potential
overestimations of liver ﬁbrosis. In this line, literature data have
already emphasized a signiﬁcant reduction of TE reproducibility
in patients with chronic liver diseases due to different etiologies
and with steatosis [23]. In addition, higher LSM values in pres-
ence of liver steatosis have been already reported in some small
[25,27] and large [26] cohorts of CHC patients, even if they were
not conﬁrmed in other studies [10,24], whereas in NAFLD
patients an inverse relation was highlighted [28]. Surely, the
presence of fat droplets in the hepatocytes inﬂuences the
architectural structure of the liver, thus potentially changing4 vol. 61 j 523–529
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Fig. 2. Liver stiffness values distribution. Within patients with F0–F2 ﬁbrosis
stages (A) and F3–F4 ﬁbrosis stages (B), and within patients with F0–F3 ﬁbrosis
stages (C) and cirrhosis (D), according to presence or absence of moderate-severe
steatosis. The horizontal bar inside the box represents the mean value.
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Fig. 3. Liver stiffness values distribution. Within patients with F0–F2 ﬁbrosis
stages (A) and F3–F4 ﬁbrosis stages (B), and within patients with F0–F3 ﬁbrosis
stages (C) and cirrhosis (D), according to presence or absence of Bright Liver Echo
Pattern (BLEP) on ultrasound. The horizontal bar inside the box represents the
mean value.
JOURNAL OF HEPATOLOGYthe propagation time of the vibratory wave through the liver,
which is the key principle of TE. Nonetheless, the reason why this
interference translated in a greater ‘‘softness’’, as observed in
NAFLD patients [28], or conversely in a higher ‘‘hardness’’, as
reported in our G1 CHC cohort, is not clear. Furthermore, we
reported that the rates of false positive LSM results for the diag-
nosis of severe ﬁbrosis and cirrhosis were strongly affected by the
presence of moderate-severe steatosis. By contrast, a recent study
on a multicenter large cohort of CHC patients [26] showed that
the presence of signiﬁcant steatosis induced false positive results
in patients with F0–F1 ﬁbrosis only, while it did not increase the
rate of F0–F3 patients misclassiﬁed as cirrhotic. Differences in the
prevalence of liver steatosis, and in the methods used to quantify
both steatosis and ﬁbrosis could explain the observed differences.
In fact, Boursier and colleagues assessed all histological features
by computerized morphometry, a technique reported as more
sensitive than optical analysis [33], but not yet standardized
and not used in clinical practice.
However, all the above quoted data raised the paradoxical
problem that the performance of a non-invasive tool – TE – is
affected by a variable – steatosis – arising from an invasive tool
– liver biopsy. To overcome this issue, we tested the impact of
a non-invasive evaluation of hepatic steatosis – US detection of
BLEP – on TE performance. Accordingly, the most relevant ﬁnding
arising from our analysis lies in the correlation of BLEP detection
with both higher LSM values and false positive results. Speciﬁ-
cally, when patients were divided according to presence or
absence of BLEP on US, we found that the variations of LSM values
and of TE accuracy were comparable with those observed when
our cohort was splitted according to presence or absence ofJournal of Hepatology 201moderate-severe steatosis, although at a slightly lesser extent.
Provided that accuracy of US for the detection of steatosis is quite
low in settings of CHC, especially due to poor PPVs for moderate-
severe degrees of steatosis, as our group recently reported [7], we
could speculate that BLEP may not be only the US expression of
histological steatosis, but also of other known – liver necroin-
ﬂammation, for example – or unknown factors able to increase
LSM independently from the amount of ﬁbrosis.
Consequently, from a clinical standpoint, our study suggests
to interpret with caution TE ﬁndings in G1 CHC patients with
detection of steatosis on US, in which LSM values could lead to
an overestimation of liver ﬁbrosis (Fig. 5). Interestingly, we
obtained a clear decrease of false positive LSM results for the
diagnosis of cirrhosis in patients with BLEP using a speciﬁc LSM
cut-off value in this subgroup. Anyway, it should be acknowl-
edged that the poor accuracy of US for the detection of steatosis
in this setting represents a limitation when using US paired with
LSM, since we risk losing a certain number of patients with stea-
tosis and thus with potential overestimation of ﬁbrosis assessed
by LSM. Computed tomography and magnetic resonance imaging
are able to demonstrate hepatic steatosis [34,35] and may be use-
ful in this setting, but their high costs and, for computed tomog-
raphy, the risk of radiation exposure limit their applicability in
routine clinical practice. CAP is likely a good alternative, although
it was not evaluated in this study.
We should mention that there are some other limitations in
our study. First, inter- and intra-observer agreement of LSM
and US examinations were not assessed. Second, a comparison
between histological/ultrasonographical ﬁndings and controlled4 vol. 61 j 523–529 527
Steatosis <20%
Steatosis ≥20%
50
30
40
20
10
0
%
 o
f f
al
se
 p
os
iti
ve
50
30
40
20
10
0
%
 o
f f
al
se
 p
os
iti
ve
50
30
40
20
10
0
%
 o
f f
al
se
 p
os
iti
ve
50
30
40
20
10
0
%
 o
f f
al
se
 p
os
iti
ve
Steatosis <20%
Steatosis ≥20%
No BLEP
BLEP
No BLEP
BLEP
A C
64/357 30/85 70/422 51/131
57/311 37/132 66/368 55/185
F0-F2
LSM <8.95 kPa 349
LSM >8.95 kPa 94 FP
Total 443
F0-F3
LSM <10.65 kPa 432
LSM >10.65 kPa 121 FP
Total 553
B DF0-F2
LSM <8.95 kPa 349
LSM >8.95 kPa 94 FP
Total 443
F0-F3
LSM <10.65 kPa 432
LSM >10.65 kPa 121 FP
Total 553
Fig. 4. Distribution of false-positive LSM results. In patients without severe
ﬁbrosis (F0–F2) according to presence or absence of moderate-severe steatosis (A)
and to detection of Bright Liver Echo Pattern (BLEP) on ultrasound (B), and in
patients without cirrhosis (F0–F3) according to presence or absence of moderate-
severe steatosis (C) and to detection of Bright Liver Echo Pattern (BLEP) on
ultrasound (D). (This ﬁgure appears in colour on the web.)
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Fig. 5. Proposed diagnostic algorithm on the use of ultrasound for detection
of steatosis paired with liver stiffness measurement.
Research Articleattenuation parameter (CAP) data was not performed, as above
mentioned, and the analysis of LSM was carried out using a con-
ventional M probe only, while the XL probe was not used.528 Journal of Hepatology 201Another methodological issue could reside in the accuracy of liver
biopsy examination related to sampling errors and intraobserver
and inter-observer variability; in addition, the assessment of
hepatic steatosis may be affected by the frequently uneven distri-
bution of fat throughout the liver, and the quantiﬁcation of hepa-
tic steatosis as a percentage of steatotic hepatocytes may not
represent a good marker of liver fat content because it does not
take into account number and size of lipid droplets in single
hepatocytes. A further methodological question is the potentially
limited external validity of the results for different populations
and settings. Our study included a cohort of Italian G1 CHC sub-
jects, largely overweight, who were enrolled in a tertiary referral
center for liver disease, limiting the broad application of the
results. Finally, lack of follow-up data may limit the potency of
our results.
In conclusion, although LSM is an useful and non-invasive tool
for estimating the severity of CHC, the presence of moderate-
severe steatosis, per se or evaluated by US, should always be
taken into account in order to avoid overestimations of liver
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